• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国肝细胞癌监测、诊断、治疗及生存方面的健康不平等:一项范围综述

Health inequalities in hepatocellular carcinoma surveillance, diagnosis, treatment, and survival in the United Kingdom: a scoping review.

作者信息

Mysko Christopher, Landi Stephanie, Purssell Huw, Allen A Joy, Prince Martin, Lindsay Gary, Rodrigues Steven, Irvine Jenny, Street Oliver, Gahloth Deepankar, MacLennan Sara, Piper Hanley Karen, Hanley Neil, Athwal Varinder Singh

机构信息

Manchester University NHS Foundation Trust, Manchester, UK.

University of Manchester, Manchester, UK.

出版信息

BJC Rep. 2025 Mar 3;3(1):13. doi: 10.1038/s44276-025-00126-5.

DOI:10.1038/s44276-025-00126-5
PMID:40033086
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11876667/
Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) remains a deadly cancer in the UK despite advancements in curative therapies. Societal conditions and health inequalities influence the development of chronic liver disease and outcomes from complications including HCC. Scoping this emergent evidence-base is required to inform research and solutions for the NHS.

METHODS

A PRISMA scoping review was performed up to September 2023. Articles exploring health inequalities in HCC involving the UK population were included.

RESULTS

This review has characterised axes of health inequality and their impact across the HCC care continuum in the UK. Studies predominantly employed a cohort design or population-based analyses, with meta-analyses of surveillance utilisation including only a single UK study. These methodologies provided an appropriate lens to understand longitudinal trends and identify disadvantaged groups. However, important evidence gaps remain, including exploration of patient perspectives, intersectional analyses, and statistical measures of socioeconomic inequity in HCC.

CONCLUSIONS

HCC is a rapidly growing cause of cancer mortality and disproportionally affects underserved groups, presenting a major public health concern. Further research is required to innovate and evaluate surveillance and management pathways to reduce systemic inequities. Direction is needed at the national level to improve prevention, early diagnosis and access to curative treatment.

摘要

背景

尽管在根治性治疗方面取得了进展,但肝细胞癌(HCC)在英国仍然是一种致命的癌症。社会状况和健康不平等会影响慢性肝病的发展以及包括HCC在内的并发症的预后。需要梳理这一新兴的证据基础,为英国国家医疗服务体系(NHS)的研究和解决方案提供信息。

方法

截至2023年9月进行了一项PRISMA范围综述。纳入了探讨涉及英国人群的HCC健康不平等问题的文章。

结果

本综述描述了英国HCC护理连续过程中健康不平等的维度及其影响。研究主要采用队列设计或基于人群的分析,对监测利用情况的荟萃分析仅包括一项英国研究。这些方法为理解纵向趋势和识别弱势群体提供了合适的视角。然而,仍存在重要的证据空白,包括对患者观点的探索、交叉分析以及HCC社会经济不平等的统计指标。

结论

HCC是癌症死亡率快速上升的一个原因,对服务不足的群体影响尤为严重,这是一个重大的公共卫生问题。需要进一步开展研究,以创新和评估监测及管理途径,减少系统性不平等。国家层面需要指导意见,以改善预防、早期诊断以及获得根治性治疗的机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b36b/11876667/faf88d10fb25/44276_2025_126_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b36b/11876667/b864f3db84df/44276_2025_126_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b36b/11876667/faf88d10fb25/44276_2025_126_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b36b/11876667/b864f3db84df/44276_2025_126_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b36b/11876667/faf88d10fb25/44276_2025_126_Fig2_HTML.jpg

相似文献

1
Health inequalities in hepatocellular carcinoma surveillance, diagnosis, treatment, and survival in the United Kingdom: a scoping review.英国肝细胞癌监测、诊断、治疗及生存方面的健康不平等:一项范围综述
BJC Rep. 2025 Mar 3;3(1):13. doi: 10.1038/s44276-025-00126-5.
2
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.超越黑木树:影响澳大利亚地区、农村和偏远地区的健康研究问题的快速综述。
Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881.
3
Cancer inequalities in the United Kingdom and the data used to measure them: a scoping review.英国的癌症不平等现象及其测量数据:一项范围综述
Lancet Reg Health Eur. 2025 Mar 4;52:101246. doi: 10.1016/j.lanepe.2025.101246. eCollection 2025 May.
4
Exploring social determinants and hepatocellular carcinoma: a scoping review of evidence and implications.探索社会决定因素与肝细胞癌:证据及影响的范围综述
Proc (Bayl Univ Med Cent). 2024 Oct 17;38(1):53-60. doi: 10.1080/08998280.2024.2406030. eCollection 2025.
5
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
6
Reducing health inequalities through general practice: a realist review and action framework.通过全科医疗减少健康不平等:一个现实主义综述和行动框架。
Health Soc Care Deliv Res. 2024 Mar;12(7):1-104. doi: 10.3310/YTWW7032.
7
Improving hepatocellular carcinoma surveillance in the United Kingdom: challenges and solutions.改善英国肝细胞癌监测:挑战与解决方案
Lancet Reg Health Eur. 2024 Jun 15;43:100963. doi: 10.1016/j.lanepe.2024.100963. eCollection 2024 Aug.
8
Socioeconomic inequalities in diagnostics, care and survival outcomes for hepatocellular carcinoma in Sweden: a nationwide cohort study.瑞典肝细胞癌诊断、治疗及生存结局中的社会经济不平等:一项全国队列研究
Lancet Reg Health Eur. 2025 Mar 20;52:101273. doi: 10.1016/j.lanepe.2025.101273. eCollection 2025 May.
9
Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.早期和极早期肝细胞癌的消融和非手术治疗:系统评价和网络荟萃分析。
Health Technol Assess. 2023 Dec;27(29):1-172. doi: 10.3310/GK5221.
10
Eating disorders in minority ethnic populations in Australia, Canada, Aotearoa New Zealand and the UK: a scoping review.澳大利亚、加拿大、新西兰和英国少数族裔群体中的饮食失调:一项范围综述。
J Eat Disord. 2025 Jan 14;13(1):8. doi: 10.1186/s40337-024-01173-y.

本文引用的文献

1
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.英国胃肠病学会成人肝细胞癌管理指南。
Gut. 2024 Jul 11;73(8):1235-1268. doi: 10.1136/gutjnl-2023-331695.
2
25 year trends in cancer incidence and mortality among adults aged 35-69 years in the UK, 1993-2018: retrospective secondary analysis.25 年来英国 35-69 岁成年人癌症发病率和死亡率趋势,1993-2018 年:回顾性二次分析。
BMJ. 2024 Mar 13;384:e076962. doi: 10.1136/bmj-2023-076962.
3
Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis.
血清生物标志物特征可预测肝硬化患者患肝细胞癌的风险。
Gut. 2024 Feb 16. doi: 10.1136/gutjnl-2024-332034.
4
Inequities in primary liver cancer in Europe: The state of play.欧洲原发性肝癌的不平等现象:现状。
J Hepatol. 2024 Apr;80(4):645-660. doi: 10.1016/j.jhep.2023.12.031. Epub 2024 Jan 17.
5
Mortality from leading cancers in districts of England from 2002 to 2019: a population-based, spatiotemporal study.2002 年至 2019 年英格兰各地区主要癌症的死亡率:一项基于人群的时空研究。
Lancet Oncol. 2024 Jan;25(1):86-98. doi: 10.1016/S1470-2045(23)00530-2. Epub 2023 Dec 11.
6
Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis.肝硬化患者肝细胞癌风险分层模型。
Clin Gastroenterol Hepatol. 2023 Dec;21(13):3296-3304.e3. doi: 10.1016/j.cgh.2023.04.019. Epub 2023 Apr 30.
7
Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes.肝癌发病率和治疗效果的种族差异。
Cancer Rep (Hoboken). 2023 Sep;6 Suppl 1(Suppl 1):e1821. doi: 10.1002/cnr2.1821. Epub 2023 Jun 21.
8
Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions.基于统计学视角探讨应用肝细胞癌风险模型辅助监测决策。
J Hepatol. 2023 Nov;79(5):1332-1337. doi: 10.1016/j.jhep.2023.05.005. Epub 2023 May 18.
9
Disparities in care and outcomes for primary liver cancer in England during 2008-2018: a cohort study of 8.52 million primary care population using the QResearch database.2008 - 2018年英格兰原发性肝癌护理与结局的差异:一项使用QResearch数据库对852万初级保健人群的队列研究。
EClinicalMedicine. 2023 May 11;59:101969. doi: 10.1016/j.eclinm.2023.101969. eCollection 2023 May.
10
Outcomes of National Survey of the Practice of Hepatocellular Carcinoma Surveillance.肝细胞癌监测实践全国调查结果
J Hepatocell Carcinoma. 2023 Apr 29;10:725-731. doi: 10.2147/JHC.S403702. eCollection 2023.